Cereno Scientific reports progress of Expanded Access Program and announces timeline adjustment in the Phase II Study of CS1 in PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an update on the progress of the Phase II study of CS1 in pulmonary arterial hypertension (PAH). Cereno has seen substantial interest in the FDA-approved Expanded Access Program (“compassionate use”) for patients who have completed the Phase II study, with investigators indicating that a majority of patients would be interested in continued access to CS1 following study completion. The company reports considerable progress in the study. Due to